Endothelial overexpression of fas ligand decreases atherosclerosis in apolipoprotein E-deficient mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 8, 2004, Pages 1466-1473

  Yang, Jiang ^a,b   Sato, Kaori ^a   Aprahamian, Tamar ^a   Brown, Nathaniel J ^c   Hutcheson, Jack ^c   Bialik, Ann ^a   Perlman, Harris ^c   Walsh, Kenneth ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Endothelium; Fas ligand; Inflammation; Transgene

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; FAS LIGAND; TRIACYLGLYCEROL;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA ARCH; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIUM CELL; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIPID DIET; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECIES COMPARISON; T LYMPHOCYTE; THORACIC AORTA; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

ANIMALS; AORTA, ABDOMINAL; AORTA, THORACIC; AORTIC DISEASES; APOLIPOPROTEINS E; APOPTOSIS; ARTERIOSCLEROSIS; DIET, ATHEROGENIC; ENDOTHELIUM, VASCULAR; FAS LIGAND PROTEIN; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; LEUKOCYTE COUNT; LIPIDS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 3943065027     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000134402.94963.2f     Document Type: Article

References (51)

1. Nagata S, Golstein P. The Fas death factor. Science. 1995;267: 1449-1456.
2. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
3. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role of CD95 ligand in preventing graft rejection. Nature. 1995;377:630-632.
4. Tourneur L, Malassagne B, Batteux F, Fabre M, Mistou S, Lallemand E, Lores P, Chiocchia G. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts. J Immunol. 2001;167:1338-1346.
5. Sata M, Luo Z, Walsh K. Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J Immunol. 2001;166:6964-6971.
6. Takeuchi T, Ueki T, Nishimatsu H, Kajiwara T, Ishida T, Jishage K, Ueda O, Suzuki H, Li B, Moriyama N, Kitamura T. Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol. 1999;162:518-522.
7. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med. 1997;3:738-743.
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (London). 1993;362:801-809.
9. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
10. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002;8:403-409.
11. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103: 773-778.
12. Emeson EE, Shen ML, Bell CG, Qureshi A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol 1996;149:675-685.
13. + T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102:2919-2922.
14. Gupta S, Palo AM, Jiang X-C, Wang N, Tall AR, Schindler C. IFNγ potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997; 99:2752-2761.
15. Geng Y-J, Henderson LE, Levesque EB, Muszynzki M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:2200-2208.
16. Cai W, Devaux B, Schaper W, Schaper J. The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis. 1997;131:177-186.
17. Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to Fas-mediated apoptosis. J Exp Med. 1999;190: 1679-1688.
18. Yao PM, Tabas I. Free cholesterol loading of macrophages induces apoptosis involving the fas pathway. J Biol Chem. 2000;275: 23807-23813.
19. Sata M, Suhara T, Walsh K. Vascular endothelial cells and smooth muscle cells differ in their expression of Fas and Fas ligand and in their sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy. Arterioscler Thromb Vasc Biol. 2000;20:309-316.
20. Henderson EL, Geng YJ, Sukhova GK, Whittemore AD, Knox J, Libby P. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation. 1999;99:96-104.
21. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, Liles WC. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol. 1997; 159:1594-1598.
22. Sata M, Perlman H, Muruve DA, Silver M, Ikebe M, Libermann TA, Oettgen P, Walsh K. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci U S A. 1998;95:1213-1217.
23. Boyle JJ, Bowyer DE, Weissberg PL, Bennett MR. Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Arterioscler Thromb Vasc Biol. 2001;21:1402-1407.
24. Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis and plaque rupture. Circ Res. 2000;87:184-188.
25. Mano T, Luo Z, Suhara T, Smith RC, Esser S, Walsh K. Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions. Hum Gene Ther. 2000;11:1625-1635.
26. Luo Z, Sata M, Nguyen T, Kaplan JM, Akita GY, Walsh K. Adenovirus-mediated delivery of Fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation. 1999;99: 1776-1779.
27. Luo Z, Garron T, Palasis M, Lu H, Belanger AJ, Scaria A, Vincent KA, Date T, Akita GY, Cheng SH, Barry J, Gregory RJ, Jiang C. Enhancement of Fas ligand-induced inhibition of neointimal formation in rabbit femoral and iliac arteries by coexpression of p35. Hum Gene Ther. 2001;12:2191-2202.
28. Newby AC, Zaltsman AB. Fibrous cap formation or destruction: the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res. 1999;41:345-360.
29. Sata M, Walsh K. TNFα regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med. 1998; 4:415-420.
30. Askenasy N, Yolcu ES, Wang Z, Shirwan H. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation. 2003;107:1525-1531.
31. Schneider DB, Vassalli G, Wen S, Driscoll RM, Sassani AB, DeYoung MB, Linnemann R, Virmani R, Dichek DA. Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol. 2000;20:298-308.
32. Sata M, Walsh K. Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J Clin Invest. 1998;102:1682-1689.
33. Yang J, Jones SP, Suhara T, Greer JJ, Ware PD, Nguyen NP, Perlman H, Nelson DP, Lefer DJ, Walsh K. Endothelial cell overexpression of fas ligand attenuates ischemia-reperfusion injury in the heart. J Biol Chem. 2003;278:15185-15191.
34. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A. 1992;89: 4471-4475.
35. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
36. Li XK, Okuyama T, Tamura A, Enosawa S, Kaneda Y, Takahara S, Funashima N, Yamada M, Amemiya H, Suzuki S. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation. 1998;66:1416-1423.
37. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A. 1994;91: 2890-2894.
38. Suzuki I, Fink PJ. The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proc Natl Acad Sci U S A. 2000; 97:1707-1712.
39. Inaba M, Kurasawa K, Mamura M, Kumano K, Saito Y, Iwamoto I. Primed T cells are more resistant to Fas-mediated activation-induced cell death than naive T cells. J Immunol. 1999;163:1315-1320.
40. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:31-36.
41. Amant C, Holm P, Xu SH, Tritman N, Kearney M, Losordo DW. Estrogen receptor-mediated, nitric oxide-dependent modulation of the immunologie barrier function of the endothelium: regulation of fas ligand expression by estradiol. Circulation. 2001;104:2576-2581.
42. Richardson BC, Lalwani ND, Johnson KJ, Marks RM. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur J Immunol. 1994;24:2640-2645.
43. Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the downregulation of the cellular caspase inhibitor FLIP. J Biol Chem. 1998;273:33103-33106.
44. Suhara T, Mano T, Oliveira BE, Walsh K. Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ Res. 2001;89:13-19.
45. Skurk C, Maatz H, Kim H-S, Yang J, Abid MR, Aird WC, Walsh K. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem. 2004;279:1513-1525.
46. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med. 1998;4:1287-1292.
47. Schaub FJ, Han DK, Liles WC, Adams LD, Coats SA, Ramachandran RK, Seifert RA, Schwartz SM, Bowen-Pope DF. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med. 2000;6:790-796.
48. Waltenberger J, Akyurek ML, Aurivillius M, Wanders A, Larsson E, Fellstrom B, Funa K. Ischemia-induced transplant arteriosclerosis in the rat: induction of peptide growth factor expression. Arterioscler Thromb Vasc Biol. 1996;16:1516-1523.
49. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L. Expression of transforming growth factor β1 is increased in human vascular restenosis. J Clin Invest. 1992;90:1582-1592.
50. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor ā1 during repair of arterial injury. J Clin Invest. 1991;88:904-910.
51. Chen J-J, Sun Y, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 1998;282:1714-1717.